Since age and gender have been introduced as the most prominent variables in assessing cognitive impairment (Podcasy and Epperson, 2016), we need compelling data to support any age- and gender-tailored recommendation for PCSK9 inhibitors. The gene discussed is PCSK9; the disease is Cognitive impairment.